TYRA - Tyra Biosciences, Inc.
About Tyra Biosciences, Inc. (https://www.tyra.bio)
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Todd Harris | Co-Founder, CEO, President & Director | 1979 | $998,960 USD |
| Douglas Warner | Chief Medical Officer | 1972 | $764,683 USD |
| Alan Fuhrman | Chief Financial Officer | 1957 | $763,093 USD |
| Daniel Bensen | Co-Founder & Chief Discovery Officer | 1975 | $737,643 USD |
| Ali D. Fawaz | General Counsel & Secretary | – | $629,230 USD |
| Bhavesh Ashar | Chief Operating Officer | 1969 | $551,017 USD |
| Ronald V. Swanson | Chief Scientific Officer | 1963 | $536,188 USD |
| Julia Rueb | VP of Finance & Principal Accounting Officer | 1986 | – |
| Liz Pagano | Chief Human Resources Officer | – | – |
| Robert L. Hudkins | Chief Technology Officer | 1955 | – |
| Sarah Honig | Senior Vice President of Corporate Development & Strategy | – | – |